Anzeige
Mehr »
Login
Freitag, 17.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
186 Leser
Artikel bewerten:
(1)

Versapay Appoints Gaby Kozakov as Chief Technology Officer

Finanznachrichten News

Kozakov will spearhead cutting-edge technology to scale customer solutions and business innovation at Versapay

MIAMI, FL / ACCESSWIRE / April 2, 2024 / Versapay, the leading Accounts Receivable Efficiency Suite, today announced that Gaby Kozakov has been appointed as its new Chief Technology Officer (CTO). Kozakov will be responsible for leveraging innovative technology to build solutions that help scale and evolve Versapay's offerings to meet the demands of our customers and the ever-changing office of the CFO in today's digital era.

"The addition of Gaby to our executive team fortifies our position to accelerate helping our customers do more with less," said Carey O'Connor Kolaja, Versapay's CEO. "He is a proven technology leader with a history of transforming growth companies and creating business value for diverse customer bases. Gaby's technical expertise and ability to be a culture carrier and change agent will provide tremendous momentum to our team. He is well positioned to lead us into this next chapter of our growth and innovation in the rapidly changing fintech space."

With more than 25 years of experience at the forefront of technological advancement, Kozakov brings deep expertise in artificial intelligence (AI) and machine learning (ML) to Versapay. In his previous roles, Kozakov also consistently covered areas like modern full-stack and native mobile development, deep learning-based computer vision, and development operations.

Notably, Kozakov served as the Vice President of Research and Development at Revuze. Prior to that, Kozakov held leadership positions at several tech-forward organizations, including Chief Technology Officer at AU10TIX, Vice President at Trax Retail, and R&D Director at Amdocs.

"I'm honored to have the opportunity to take on the role of Chief Technology Officer at Versapay," said Gaby Kozakov. "I'm looking forward to working with the talented engineers and product team members to drive meaningful innovation for Versapay and its customers as we lead the way in accounts receivable automation."

Kozakov holds a B.A. degree in Computer Science from Open University of Israel. While working at Comverse, Gaby graduated Comverse's Global Leadership Program (GLP) and Comverse's Business Training at LAHAV (Tel-Aviv University).

For more information on Versapay, visit versapay.com.

About?Versapay

For growing businesses that need to accomplish more with less, Versapay's Accounts Receivable Efficiency Suite simplifies the invoice-to-cash process by automating invoicing, facilitating B2B payments, and streamlining cash application with AI. Versapay integrates natively with top ERPs, while allowing businesses to collect with a self-serve payment portal and collaborate with customers and teammates to resolve what automation alone can't. Owned by Great Hill Partners, Versapay's employee base spans the U.S. and Canada with offices in Atlanta and Miami. With 10,000 customers and 5M+ companies transacting, Versapay facilitates 110M+ transactions and processes $170B+ in payments volume annually.

Join the conversation at twitter.com/Versapay and linkedin.com/company/versapay. To learn more about Versapay and its collaborative AR solutions please visit: versapay.com.

Versapay Media Contact
Sarah Weaver
Caliber Corporate Advisers
versapay@calibercorporateadvisers.com

SOURCE: Versapay



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.